Skip to main content

Recent News & Research

OncLive
ResearchTreatments

Dr. Spira on the Further Investigations of Lazertinib/Amivantamab in EGFR-Mutant NSCLC

*August 2022* Alexander I. Spira, MD, PhD, FACP, research institute director, Thoracic and Phase 1 Trial Program, Virginia Cancer Specialists Research Institute, Virginia Cancer Specialists, clinical assistant professor, Johns Hopkins University, discusses additional studies investigating the use of lazertinib (Leclaza) and amivantamab-vmjw (Rybrevant) in EGFR-mutated non–small cell lung cancer (NSCLC).…
laurabbook@gmail.com
September 25, 2022
IASLC
ResearchTreatments

Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations

*August 2022* From WCLC Abstract presented by Dr. Jie Huang Introduction: Small cell lung cancer (SCLC) transformation remains one of the unsettled resistant mechanisms for lung adenocarcinoma (LUAD), of which co-occurring TP53 and RB1 mutations defined a subgroup of patients with increased risk of SCLC transformation. Our study aimed to…
laurabbook@gmail.com
September 25, 2022
ResearchTreatments

EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents

*September  2022* In this issue of the Journal of Thoracic Oncology, Piccirillo et al. report the results of the BEVERLY trial, a randomized phase 3 study that reveals the progression-free survival (PFS) benefit of bevacizumab to erlotinib as first-line treatment for Italian patients with metastatic NSCLC with common EGFR mutations. In this large study, after…
laurabbook@gmail.com
September 25, 2022
FDA Food and Drug Admin Logo
ResearchTreatments

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer

*August 2022* On August 11, 2022, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as detected by an…
laurabbook@gmail.com
September 25, 2022
lungcancer.net
Coping With Cancer

Being Courageous Is A Real Choice

By Lalaine Alfaro for Lungcancer.net How can you get ready to do something though being scared to death or most frightened? Despite fear you still have the ability to be useful. There are moments I feel a great deal of fear and anxiety about the situations or choices when living…
laurabbook@gmail.com
September 25, 2022
lung cancer research foundation
Coping With Cancer

#TogetherSeparately: Surviving Survivorship

*August 2022* Dr. Isabel Preeshagul was joined by Dr. Marleen Meyers and EGFR Resisters co-founder Jill Feldman for the LCRF Lung Cancer Community Talk. Topics focused on ways to manage physical and emotional side effects, including coping with anxiety and fear, and a discuss on social and financial challenges that…
laurabbook@gmail.com
September 24, 2022
lungevity
ResearchTreatments

How to Read Biomarker Test Results

Biomarker testing is used among diagnosed patients with  non-small cell lung cancer (NSCLC) to determine the presence of specific mutations or proteins associated with cancer. It ensures that patients get matched to the right treatment at the right time, based on their biomarker test results. The results can also provide…
laurabbook@gmail.com
September 24, 2022